Afala
Producer: LLC NPF Materia Medika Holding Russia
Code of automatic telephone exchange: G04BX
Pharm group: a href="javascript:if(confirm(%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=108 \n\nThis file was not retrieved by Teleport Pro, because it is linked too far away from its Starting Address. If you increase the in-domain depth setting for the Starting Address, this file will be queued for retrieval. \n\nDo you want to open it from the server?%27))window.location=%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=108%27" tppabs="medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=108">Drugs for treatment of urological diseases
Release form: Firm dosage forms. Tablets.
General characteristics. Structure:
Active ingredients: antibodies to prostatospetsifichesky antigen affinely cleared – 0.003g.
Excipients: lactose, cellulose microcrystallic, magnesium stearate.
Tablets of a ploskotsilindrichesky form, with risky and a facet, from white till almost white color. On the flat party from risky MATERIA MEDICA text is put, on other flat party AFALA text is put.
Pharmacological properties:
Reduces the phenomena of an inflammation and hypostasis in a prostate, normalizes its functional state. Improves urodynamic, reduces the volume of a residual urine, normalizes a tone of lower parts of urinary tract, promotes reduction of dysuric frustration.
Indications to use:
Benign hyperplasia of a prostate of I and II stages.
As a part of complex therapy of acute and chronic prostatitis – as antiinflammatory and anesthetic.
The dysuric frustration (frequent desires on an urination, including night, difficulty at an urination, pain or discomfort in a crotch) including accompanying a benign hyperplasia of a prostate of I and II stages; acute and chronic prostatitis.
Route of administration and doses:
Inside. On one reception 2 tablets (to hold in a mouth before full dissolution - not during meal). To accept drug twice a day, in the evening and in the morning (before and after a dream). The recommended duration of administration of drug - 16 weeks.
At the expressed pain syndrome and dysuric disturbances in the first 2 - 3 weeks of therapy administration of drug to 4 times a day is shown.
If necessary according to the recommendation of the doctor carrying out a repeated course of treatment in 1 - 4 month is possible.
Features of use:
Lactose in this connection patients are not recommended to appoint it with an inborn galactosemia, a sprue of glucose or a galactose, or at an inborn lactose intolerance is a part of drug.
Side effects:
When using drug according to the specified indications and in the specified dosages of side effect it is not revealed.
Interaction with other medicines:
Cases of incompatibility with other medicines are not registered so far.
Contraindications:
The increased individual sensitivity to drug components.
Overdose:
At accidental overdose the dispepsichesky phenomena caused by the fillers which are a part of a dosage form are possible.
Storage conditions:
In the dry, protected from light place, at a temperature not above 25ºС. To store in the place, unavailable to children. Period of validity 3 years. Not to apply after a period of validity.
Issue conditions:
Without recipe